BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380-1384. [PMID: 25229983 DOI: 10.1097/meg.0000000000000197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol. 2017;23:3367-3373. [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
2 Song Y, Dou F, Zhou Z, Yang N, Zhong J, Pan J, Liu Q, Zhang J, Wang S. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. Biomed Res Int 2018;2018:2684836. [PMID: 30276203 DOI: 10.1155/2018/2684836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Graham DY. Editorial--Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants. Helicobacter 2015;20:321-5. [PMID: 26123529 DOI: 10.1111/hel.12244] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-13437. [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
5 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
6 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017;23:2854-69. [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]